Infrastructure to Enable Holistic Patient Support Services
White Papers
Case Study: Designing patient support programs that deliver on their promise
Evolving Trends in Patient Services
Building a Strong Portfolio of Products with Co-positioning
Herspiegel Consulting Expands Market Access Services
Creating Clear Co-positioning Lanes to Optimize Portfolio Performance
Roadmap to De-risk Commercialization of a Rare Disease Product
Navigating a Drug Launch in 2022: Best Practices to De-risk Your Launch Plan
Proven Pharmaceutical Go-To-Market Model
The Four Key Elements of Successful Product Planning
Cracking the Code: Creating a Support Program Where Patients Start, Stay and Succeed
Herspiegel Consulting Promotes Senior Biopharma Expert to Principal
Navigating a Drug Launch in 2022: Part 4 – The Launch Plan
Commercial Launch Readiness for Pharmaceutical and Biotechnology Start-Ups
Navigating a Drug Launch in 2022: Part 3 – How to execute
Market Access Trends for Launch Success
Navigating a Drug Launch in 2022: Part 2 – How to Win
Navigating a Drug Launch in 2022: Part 1 – Where to Play?
5 Ways the Build Back Better Act Will Reduce Costs
Herspiegel Consulting Closes Growth Investment from DFW Capital Partners
Evolution of Drug Launch Strategies During Covid-19
Herspiegel Consulting Named One of the 2021 Best Places to Work in Pennsylvania
Transforming Patient Services in Pharma: 5 winning strategies
Verix and Herspiegel Consulting Announce Strategic Partnership
10 Drug Launches to Watch in 2021
Biosimilar Commercialization: Getting it Right in the Pharma Patent Landscape
Mainstreaming Cell and Gene Therapy Commercialization
XTalks Sponsored: Rare Disease Drug Launch – Lessons Learned to Ensure Success is Not a Rare Event
Webinars
XTalks Sponsored: Oncology Product Launch – The Toolkit for Success
XTalks Sponsored: Pharmaceutical Commercial Launch Readiness, Secrets to De-Risk and Accelerate Success
XTalks Sponsored: COVID19 Navigating the New Normal in Pharmaceutical Commercialization II
COVID19 Navigating the New Normal in Pharmaceutical Commercialization I
COVID-19 Implications for Patient Care and Payers
Adversity Inspired Change: The Opportunity for Pharma in Telehealth Amid and Beyond COVID-19
Digital Therapeutics Commercialization Tips and Challenges
Evolving Access Considerations for Rare Diseases
Government Intervention into Drug Pricing: Part 4
Government Intervention into Drug Pricing: Part 3
Government Intervention into Drug Pricing: Part 2
Government Intervention into Drug Pricing: Part 1
Herspiegel Consulting Expands Market Access Support for Clients
CREATES Act Hopes to Spur Generic Competition in Pharmaceutical Market
Performance Metrics Point Of View
Cigna’s Initiative to Lower the Out-Of-Pocket Cost of Insulin
The Four Key Elements of Successful New Product Planning
Celebrating International Women’s Day
Innovative Drug Pricing via “Netflix Model”
FDA Real-World Evidence Program Framework: Implications for Pharmaceutical Companies
Copay Accumulators & Maximizers
Digital Health in Pharma
Planning for 505(b)2 Commercial Success
Fed-Up Hospitals are Starting Their Own Drug Company to Lower Generic Drug Prices
FDA Continued Rejections of Citizen Petitions Highlights Key Lifecycle Challenges for Biologic Manufacturers
The FDA approved Dupixent for moderate-to-severe atopic dermatitis
Highly Anticipated Drug Launches in 2017
Why Drug Pricing is in the News Now and What Can Be Done About It?
Getting the Most of Consulting Engagements
Innovation in Pharma
Key Challenges Facing Obamacare Repeal and Replace Plan
How Pharma Can Prepare for the Patent Cliff
Innovation in Pharma Sees Drop in 2016
3 Pillars To Support A Winning Product Launch
Vermont Drug Price Transparency Bill
Biking for a World Without Diabetes
